Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4558 Prognostic impact of primary tumour location after resection of neuroendocrine liver metastases from gastroenteropancreatic tumours

Introduction: Little evidence however exists regarding the prognostic impact of localisation of the primary tumour in case of neuroendocrine liver metastasis (NELM).

Conference:

Presenting Author: Coppa J

Authors: Simonotti N, Coppa J, Maspero M, Paoletti M, Pezzoli I,

Keywords: neuroendocrine liver metastasis, liver resection, hepatic surgery, pancreatic net, gastroenteropancreatic neuroendocrine tumour,

#3848 LITESPARK-015 cohort B1 – A phase 2 open-label study of Belzutifan (a HIF-2α inhibitor) monotherapy in patients with von Hippel-Lindau (VHL) disease–associated tumors

Introduction: Patients (pts) with von Hippel-Lindau (VHL) disease need novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in VHL disease. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in pts with advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors (pNETs); more data are needed in VHL disease–associated localized tumors.

Conference:

Presenting Author:

Authors: Walter T, Gong K, Nakamura E, Iliopoulos O, Jimenez C,

Keywords: von Hippel-Lindau disease, belzutifan, MK-6482,

#3696 The characteristics of serum lipid spectrum in PanNENs and its correlation with clinicopathological features and prognosis

Introduction: Although dyslipidemia has been proved to be related to the occurrence, development, and prognosis of various malignancies, its role in pancreatic neuroendocrine neoplasms (PanNENs) is still unknown.

Conference:

Presenting Author: Meng Y

Authors: Meng Y, Fan Z, Yang J, Li Y, Liu S,

Keywords: Hyperlipidaemia, Insulinoma, Lipid, Pancreatic neuroendocrine neoplasm,

#3360 The risk factors of lymphovascular invasion in rectal neuroendocrine tumors

Introduction: Rectal neuroendocrine tumors (rNETs) have the malignant potential of lymph node metastasis and distant metastasis.

Conference:

Presenting Author:

Authors: Liu T, Hu H, Zong Y, Li P,

Keywords: rectal neuroendocrine tumor, lymphovascular invasion, endoscopic manifestations, risk factor,

#3283 Tumor growth rate in well-differentiated G1-3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Implications for clinical trials

Introduction: Drug development in G1-3 GEP-NETs is hampered by heterogeneous tumor biology and the cytostatic nature of most active agents. Optimal care of G3NETs is ill-defined, as recent phase 3 studies have not accounted for this group. Tumor growth rate (TGR) allows dynamic evaluation of growth and has prognostic value in G1-2; little is known about TGR in G3.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Wang S, Whitman J, Paciorek A, Le B, Zhang L,

Keywords: GEP-NET, tumor growth rate, Ki67,